Pulmonary Large Cell Neuroendocrine Carcinoma

Area of Science:

• Oncology
• Pulmonary Medicine
• Pathology

Background:

• Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare lung cancer subtype (0.3%-3% of lung cancers).
• Despite classification as non-small cell lung cancer (NSCLC), LCNEC exhibits aggressive behavior similar to small cell lung cancer (SCLC).
• Typical patients are elderly males who smoke, presenting with non-specific symptoms.

Purpose of the Study:

• To provide a comprehensive overview of LCNEC.
• To cover epidemiological features, imaging, pathology, diagnosis, treatment, and prognosis.
• To highlight recent advances in molecular typing for diagnosis and treatment.

Main Methods:

• Review of epidemiological data.
• Analysis of imaging findings (peripheral and upper lobe location, lymph node enlargement).
• Focus on pathological diagnosis using histology and immunohistochemistry (IHC) with markers like CgA, Syn, CD56, INSM1, and Ki-67.

Main Results:

• LCNEC presents with non-specific clinical and imaging features, often in the periphery and upper lobes.
• Diagnosis relies on histology and IHC, with specific neuroendocrine markers being crucial.
• Differential diagnoses can complicate accurate LCNEC identification.

Conclusions:

• Accurate diagnosis of LCNEC requires careful pathological examination and consideration of IHC markers.
• Molecular typing is emerging as a valuable tool for LCNEC diagnosis and treatment selection.
• Further research into LCNEC's unique characteristics is essential for improving patient prognosis.